Thompson Siegel & Walmsley LLC Rocket Pharmaceuticals, Inc. Transaction History
Thompson Siegel & Walmsley LLC
- $5.95 Billion
- Q1 2025
A detailed history of Thompson Siegel & Walmsley LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Thompson Siegel & Walmsley LLC holds 46,747 shares of RCKT stock, worth $129,489. This represents 0.01% of its overall portfolio holdings.
Number of Shares
46,747
Previous 12,747
266.73%
Holding current value
$129,489
Previous $160,000
95.0%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RCKT
# of Institutions
258Shares Held
108MCall Options Held
555KPut Options Held
177K-
Rtw Investments, LP New York, NY17.7MShares$49 Million1.93% of portfolio
-
Wellington Management Group LLP Boston, MA12.6MShares$35 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$17.2 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$14.4 Million0.68% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $210M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...